Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$0.03.

  • Verrica Pharmaceuticals' EPS (Basic) rose 9938.52% to -$0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.37, marking a year-over-year increase of 21893.31%. This contributed to the annual value of -$1.43 for FY2024, which is 360.24% up from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' EPS (Basic) stood at -$0.03, which was up 9938.52% from $0.02 recorded in Q2 2025.
  • Verrica Pharmaceuticals' EPS (Basic)'s 5-year high stood at $0.02 during Q2 2025, with a 5-year trough of -$4.88 in Q3 2024.
  • Over the past 5 years, Verrica Pharmaceuticals' median EPS (Basic) value was -$0.31 (recorded in 2022), while the average stood at -$0.68.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 2632248.0% in 2023, then soared by 10054.05% in 2025.
  • Verrica Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.35 in 2021, then soared by 60.31% to -$0.14 in 2022, then crashed by 285.71% to -$0.54 in 2023, then soared by 51.55% to -$0.26 in 2024, then surged by 88.53% to -$0.03 in 2025.
  • Its EPS (Basic) was -$0.03 in Q3 2025, compared to $0.02 in Q2 2025 and -$0.1 in Q1 2025.